No Data
HUTCHMED Shares Rise as Lung Cancer Drug Trial Hits Key Targets | AIM:HCM, NASDAQ:HCM, HKG:0013
AstraZeneca Reports Mixed Lung Cancer Trial Outcomes From Three Pivotal Studies
At a Glance: Stocks Gapping up Premarket
Hong Kong Stocks Rise on Monday on Tech Gains; Alibaba Rises 2%
Summary of HK Stock Ratings: China Merchants Securities (Hong Kong) Maintains Buy Rating on Zhipu
Cailian Press will regularly compile ratings and target prices for Hong Kong-listed stocks issued by various institutions.
Hutchmed Reports Positive Phase 3 Trial Results for Non-small Cell Lung Cancer Combination Therapy